San Francisco-based Versant Ventures debuted Jecure Therapeutics on Feb. 15, 2017.
Here's what you need to know.
1. Jecure is a biotech company with a proprietary liver disease platform. To date, it has developed treatment programs for non-alcoholic steatohepatitis and fibrosis.
2. Versant committed $20 million to Jecure and was the sole investor in a series A funding round.
3. Jecure CEO Jeffrey Stafford, PhD, and James Veal, PhD, founded Jecure and were senior managers at a cancer company which Versant founded.
4. Dr. Stafford said, "The series A backing of Jecure renews a successful partnership with Versant, and provides us the opportunity to build another transformational company in a field that is starving for innovation. We continue to have ongoing discussions with strategic and financial partners while we independently build a pipeline of drug candidates based on the discoveries from the UCSD NASH platform."
More articles on gastroenterology:
4 GI devices receive FDA clearance in January 2017
GI leader to know: Dr. David Freeto of Queen of the Valley Medical Center
ArQule's, Daiichi Sankyo's hepatocellular carcinoma drug fails to improve survival in HCC patients